To the full analysis
Buyback calculator for Sanara MedTech
Sanara MedTech Stock: Key Metrics
SMTISanara MedTech had an operating margin of 8.9% and a return on invested capital (ROIC) of 15.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 20 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | −1.7% | −257.1% | −328.6% |
| 2007 | 64.6% | −64.4% | −86.1% |
| 2008 | −43.7% | −606.1% | −611.1% |
| 2009 | −283.7% | −639.6% | −799.4% |
| 2010 | 40.9% | −337.2% | −564.1% |
| 2011 | 63.8% | −226.9% | −576.6% |
| 2012 | 32.0% | −461.7% | −157.2% |
| 2013 | 54.1% | −169.6% | −240.3% |
| 2014 | 69.5% | −78.3% | −86.5% |
| 2015 | 73.5% | −28.6% | −39.8% |
| 2016 | 82.9% | −4.9% | −7.5% |
| 2017 | 87.2% | 1.9% | 5.3% |
| 2018 | 91.3% | −8.6% | −10.3% |
| 2019 | 89.7% | −23.3% | −23.9% |
| 2020 | 89.6% | −32.3% | −27.9% |
| 2021 | 90.4% | −30.6% | −32.8% |
| 2022 | 86.1% | −27.3% | −17.3% |
| 2023 | 87.9% | −6.5% | −6.6% |
| 2024 | 90.6% | −7.7% | −11.2% |
| 2025 | 90.1% | 8.9% | no data |
Returns on Capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 49.1% | no data | −100.0% |
| 2007 | 29.9% | no data | −100.0% |
| 2008 | 200.0% | no data | −100.0% |
| 2009 | −99.5% | −59.8% | −48.2% |
| 2010 | −100.0% | −53.4% | −75.7% |
| 2011 | 200.0% | no data | −100.0% |
| 2012 | 48.5% | no data | −100.0% |
| 2013 | 168.0% | no data | −100.0% |
| 2014 | 200.0% | no data | −100.0% |
| 2015 | 105.4% | no data | −96.3% |
| 2016 | 98.3% | −58.8% | −19.1% |
| 2017 | 200.0% | 20.1% | 14.9% |
| 2018 | −54.0% | −29.2% | −19.7% |
| 2019 | −42.5% | −38.9% | −25.3% |
| 2020 | −70.8% | −53.9% | −44.3% |
| 2021 | −25.9% | −65.5% | −21.8% |
| 2022 | −19.0% | −43.5% | −13.0% |
| 2023 | −9.6% | −7.9% | −5.8% |
| 2024 | −24.5% | −10.0% | −11.0% |
| 2025 | no data | 15.6% | no data |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
